Shareen's research sits within the College ‘Biomarkers and Genes’ Theme.

Shareen is Director of the Centre for NanoHealth and she leads the In Vitro Toxicology Group, within which she heads the Nano(geno)toxicology and Prostate Cancer research programs.

Shareen’s research interests focus on the genotoxic profiles of engineered nanomaterials, the mechanisms underlying their DNA damaging potential and subsequent consequences upon human health. Her interests extend to the development of advanced 3D culture models and mechanism-based bioassays for safety assessment to reduce the need for animal testing.  While her prostate cancer research focuses on understanding the molecular basis of progression to invasive, aggressive disease; with an ultimate aim of identifying a prognostic biomarker panel for improved clinical management of patients.

Shareen sits on the UK Government Committee on Mutagenicity (COM), and is the Nanomaterials Working Group Co-Leader for the International Genetic Toxicology Technical Committee (GTTC). She is also a member of the editorial boards of Mutagenesis and Mutation Research (Genetic Toxicology).

Her research career to date in the fields of genotoxicology and translational cancer research has led to the UK (2008) and European (2009) Environmental Mutagen Society “Young Scientist Awards” and the Welsh Livery Guild Merit Award (2013). Shareen is a UK and EUROTOX Registered Toxicologist, and an invited Fellow of the Royal Society of Biology (FRSB).

Areas of Expertise

  • Genetic Toxicology
  • Nanotoxicology
  • DNA Damage Mechanisms
  • Biomarkers / Molecular Biology of Prostate Cancer

Publications

  1. & Characterizing Nanoparticles in Biological Matrices: Tipping Points in Agglomeration State and Cellular Delivery In Vitro. ACS Nano
  2. & Aligning nanotoxicology with the 3Rs: What is needed to realise the short, medium and long-term opportunities?. Regulatory Toxicology and Pharmacology
  3. & Tissue-Engineered Solutions in Plastic and Reconstructive Surgery: Principles and Practice. 4
  4. & Investigation of J-shaped dose-responses induced by exposure to the alkylating agent N -methyl- N -nitrosourea. Mutation Research/Genetic Toxicology and Environmental Mutagenesis
  5. & Choose your cell model wisely: The in vitro nanoneurotoxicity of differentially coated iron oxide nanoparticles for neural cell labeling. Acta Biomaterialia
  6. & Genetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDerm™). Particle and Fibre Toxicology 13(1)
  7. & Coating of Quantum Dots strongly defines their effect on lysosomal health and autophagy. Acta Biomaterialia
  8. Opinion of the Scientific Committee on consumer safety (SCCS) - Opinion on the use of 2,2′-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol) (nano) – S79 – In cosmetic products. Regulatory Toxicology and Pharmacology 76, 215-216.
  9. Wills JW, Johnson GE, Doak SH, Soeteman-Hernández LG, Slob W, White PA Empirical analysis of BMD metrics in genetic toxicology part I: in vitro analyses to provide robust potency rankings and support MOA determinations..
  10. & Quantum dot induced cellular perturbations involving varying toxicity pathways. Toxicol. Res.

See more...

Teaching

  • PM-304 Biomolecular Research Project

    *

  • PM-M16 Nano(geno)toxicology

    Nano(geno)toxicology is a new discipline that has recently evolved with the development of the nanotechnology industry. This subject encompasses general toxicology associated with nanomaterials and also specifically focuses on the sub-discipline of genotoxicology. This course will therefore focus on, (I) the parameters of engineered nanomaterials that govern their interaction and influence on biological systems; (II) techniques that are central elements in assessing the safety evaluation of nanomaterials; (III) portals of entry into the body, their potential fate and the mechanisms that underlie cellular damage by nanomaterials.

  • PM-M28 Nano(geno)toxicology

    PM-M28 is a Taught Masters level module that focusses upon the field of Nanoparticle (geno)toxicology. The module is worth 20 credits. It occurs in the second semester, and is administered through both lecture-based and practical components. Students are taught by a variety of lecturers from academia, industry and clinical medicine. Students are assessed via both coursework (two (2) pieces) and examination. Briefly, Nano(geno)toxicology is a new, multi-interdisciplinary discipline that has evolved concomitantly with the development of the nanotechnology industry. The syllabus of this taught module encompasses general toxicology associated with nanomaterials (hazard and exposure assessments), their genetic toxicology implications, their physical and material properties as well as their applied formulations and scenarios. The module further provides insight into all these areas from the view of not only academia, but also industry and clinical medicine.

Supervision

  • 'The role of STEAP2 in Prostate Cancer Progression' (current)

    Student name:
    PhD
    Other supervisor: Dr Claire Morgan
  • Development of a novel in vitro liver 3D model to assess potential (geno)toxicity of nanomaterials (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • 'In vitro assessment of genotoxicity and cell cycle abnormalities to better understand carcinogenic risk' (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Development and characterisation of prostate cancer spheroids for drug evaluation (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • The effect of chronic dosing regimes on genotoxic hazard identification (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Examining the Interaction between Adipose Derived Stem Cells (ADSC) and MCF-7 breast cancer in the breast microenvironment: a pilot study (current)

    Student name:
    MPhil
    Other supervisor: Prof Iain Whitaker
  • 'The molecular mechanisms for chemo-preventative effects of aspirin on prostate cancer' (current)

    Student name:
    MSc
    Other supervisor: Prof Steve Conlan
  • deducing the impact of engineered nanoparticles upon telomere length and function (current)

    Student name:
    MSc
    Other supervisor: Dr Martin Clift
  • Untitled (current)

    Student name:
    MSc
    Other supervisor: Dr Martin Clift
  • Mechanistic evaluation of the impact of superparamagnetic iron oxide nanoparticles conjugated with drugs (SPIONd) on intracellular signalling/homeostatic mechanisms (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Development of a blood based biomarker for early GI tract cancer (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Understanding the human health impacts of graphene-based nanomaterials under occupational exposure scenarios (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Untitled (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Untitled (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Untitled (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Blood based chemotherapy response monitoring (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Blood-based test for pancreatic cancer (current)

    Student name:
    PhD
    Other supervisor: Prof Gareth Jenkins
  • Untitled (current)

    Student name:
    PhD
    Other supervisor: Dr Martin Clift
  • Untitled (current)

    Student name:
    PhD
    Other supervisor: Prof Steve Conlan
  • Patient centred outcomes in post-facial skin cancer reconstruction, will tissue engineering provide an improvement in the future?” (current)

    Student name:
    PhD
    Other supervisor: Prof Hayley Hutchings
    Other supervisor: Prof Iain Whitaker
  • Mechanistic Investigation of the Epigenetic Aberrations Underlying Colorectal Cancer and its Resistance to Therapy (current)

    Student name:
    MD
    Other supervisor: Prof Gareth Jenkins

External Responsibilities

Research Groups

  • In Vitro Toxicology Group

    Our group focuses on the mechanistic basis for DNA damage induction and persistence, as well as its consequences to human health. The approaches taken by this group involve models of human mutagenesis in vitro in human cells, including genetically modified repair deficient cells, to understand basic mechanisms. Recent work has also focused on assessing 3D human liver and skin models for measuring DNA damage, coupled to automated micronucleus capabilities.

  • Nano(geno)toxicology

    Our research interests lie in understanding the mechanistic basis for DNA damage (genotoxicity) induction and persistence, as well as its consequences to human health following exposure to engineered nanomaterials. We focus on determining genotoxic potential as a function of nanomaterial physico-chemical characteristics and on developing advanced in vitro test systems suited to the assessment of these novel substances.

  • Prostate Cancer

    Our prostate cancer research activity focuses on the identification and validation of molecular biomarkers for the prediction of prostate cancer outcome and evaluating their use as drug targets. The ultimate aim is to achieve patient stratification according to risk for developing metastatic disease with such biomarkers, in order to improve the clinical management of patients.

Administrative Responsibilities

  • Director of Center for NanoHealth (CNH)

    2015 - Present

  • Member - College of Medicine Research Committee

    2012 - Present